8-K Announcements
6Material company update
Apr 7, 2026·SEC
Material company update
Mar 3, 2026·SEC
Material company update
Feb 23, 2026·SEC
TransCode Therapeutics, Inc.(RNAZ)Earnings, Financials & Key Ratios
RNAZ•NASDAQ
$8.00
$7M mkt cap·Price updated May 7, 2026
AboutTransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNAbased agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.Show more
- Revenue$0
- EBITDA-$15M+20.0%
- Net Income-$17M+9.7%
- EPS (Diluted)-47.14+98.6%
- Interest Coverage-584.07-68.1%
RNAZ Key Insights
TransCode Therapeutics, Inc. (RNAZ) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
RNAZ Price & Volume
TransCode Therapeutics, Inc. (RNAZ) stock price & volume — 10-year historical chart
Loading chart...
RNAZ Growth Metrics
TransCode Therapeutics, Inc. (RNAZ) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-81.78%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-647.37%
Return on Capital
10 Years-350.26%
5 Years-338.29%
3 Years-484.11%
Last Year-505.04%
RNAZ Peer Comparison
TransCode Therapeutics, Inc. (RNAZ) competitors in RNA and Genome Editing Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ARWR | 10.92B | 77.95 | -6389.34 | 232.58% | -48.38% | -55.47% | 0.73 | |
 NTLA | 1.62B | 13.71 | -3.60 | 16.92% | -6.1% | -56.63% | 0.14 | |
 SRPT | 2.18B | 20.80 | -2.92 | 15.58% | 2.98% | 4.89% | 0.91 | |
 MRNA | 19.25B | 48.54 | -6.69 | -39.23% | -143.55% | -36.73% | 0.22 | |
 IONS | 12.56B | 76.02 | -31.94 | 33.87% | -30.87% | -58.57% | 5.35 | |
 STRO | 338.04M | 39.83 | -1.35 | -59.64% | -205.18% | -234.19% | 0.52 | |
 CRSP | 5.06B | 52.42 | -8.10 | -89.97% | -138.57% | -30.88% | 0.21 | |
 BEAM | 3.23B | 31.47 | -38.85 | 120.01% | -49.17% | -5.89% | 0.24 |
Compare RNAZ vs Peers
TransCode Therapeutics, Inc. (RNAZ) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RNAZ Income Statement
TransCode Therapeutics, Inc. (RNAZ) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 42.47K | 98.61K | 516.75K | 534.86K | 69.4K |
| COGS % of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | -42.47K▲ 0% | -98.61K▼ 132.2% | -516.75K▼ 424.1% | -534.86K▼ 3.5% | -69.4K▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | -132.18% | -424.05% | -3.5% | - |
| Operating Expenses | 384.52K | 456.87K | 726.6K | 6.11M | 18.57M | 18.9M | 15.13M | 16.99M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 301.46K | 230.56K | 442.14K | 3.35M | 8.33M | 6.64M | 5.51M | 5.42M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - |
| Research & Development | 82.53K | 226.31K | 284.46K | 2.75M | 10.23M | 12.26M | 9.62M | 11.57M |
| R&D % of Revenue | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -384K▲ 0% | -456.87K▼ 19.0% | -726.6K▼ 59.0% | -6.15M▼ 746.6% | -18.67M▼ 203.5% | -19.42M▼ 4.0% | -15.66M▲ 19.4% | -17.05M▲ 0% |
| Operating Margin % | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -18.98% | -59.04% | -746.56% | -203.45% | -4.03% | 19.35% | - |
| EBITDA | 0 | -450.25K | -1.95M | -6.11M | -18.57M | -18.9M | -15.13M | -16.85M |
| EBITDA Margin % | - | - | - | - | - | - | - | - |
| EBITDA Growth % | - | - | -332.94% | -213.37% | -203.95% | -1.8% | 19.98% | -19.74% |
| D&A (Non-Cash Add-back) | 384K | 0 | 0 | 42.47K | 98.61K | 516.75K | 534.86K | 192.25K |
| EBIT | -384K | -450.25K | -1.95M | -6.75M | -17.56M | -18.49M | -16.73M | -27.13M |
| Net Interest Income | 0 | -156.93K | -394.44K | -94.41K | -17.54M | -50.61K | -26.13K | -7.31K |
| Interest Income | 68.92K | 34 | 136 | 664 | 20.41K | 5.29K | 684 | 600 |
| Interest Expense | 0 | 156.97K | 394.57K | 95.07K | 17.56M | 55.9K | 26.81K | 7.91K |
| Other Income/Expense | -69.44K | -150.35K | -1.62M | -692.26K | 1.1M | 872.42K | -1.09M | -10.09M |
| Pretax Income | -453.44K▲ 0% | -607.21K▼ 33.9% | -2.34M▼ 286.0% | -6.84M▼ 192.0% | -17.56M▼ 156.7% | -18.55M▼ 5.6% | -16.75M▲ 9.7% | -27.13M▲ 0% |
| Pretax Margin % | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -453.44K▲ 0% | -607.21K▼ 33.9% | -2.34M▼ 286.0% | -6.84M▼ 192.0% | -17.56M▼ 156.7% | -18.55M▼ 5.6% | -16.75M▲ 9.7% | -27.13M▲ 0% |
| Net Margin % | - | - | - | - | - | - | - | - |
| Net Income Growth % | - | -33.91% | -286.01% | -191.97% | -156.67% | -5.59% | 9.66% | -81.78% |
| Net Income (Continuing) | -453.44K | -607.21K | -2.34M | -6.84M | -17.56M | -18.55M | -16.75M | -27.13M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -2359.09▲ 0% | -72.00▲ 96.9% | -293.76▼ 308.0% | -648.00▼ 120.6% | -1080.00▼ 66.7% | -3453.53▼ 219.8% | -47.14▲ 98.6% | -32.55▲ 0% |
| EPS Growth % | - | 96.95% | -308% | -120.59% | -66.67% | -219.77% | 98.63% | -647.37% |
| EPS (Basic) | -2359.09 | -72.00 | -293.76 | -648.00 | -73187.37 | -3453.65 | -47.14 | - |
| Diluted Shares Outstanding | 192 | 6.41K | 7.98K | 10.53K | 16.22K | 5.42K | 356.12K | 833.68K |
| Basic Shares Outstanding | 192 | 6.41K | 7.98K | 10.53K | 16.22K | 5.42K | 356.12K | 833.68K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
RNAZ Balance Sheet
TransCode Therapeutics, Inc. (RNAZ) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 214.65K | 204.47K | 831.22K | 22.73M | 7.38M | 4.46M | 7.09M | 4.75B |
| Cash & Short-Term Investments | 212.98K | 204.47K | 828.02K | 20.83M | 4.98M | 2.77M | 5.81M | 2.84B |
| Cash Only | 212.98K | 204.47K | 828.02K | 20.83M | 4.97M | 2.77M | 5.81M | 2.84B |
| Short-Term Investments | 0 | 0 | 0 | 0 | 9.41K | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 1.84M | 1.02M | 1.14M | 517.48K | 1.92B |
| Total Non-Current Assets | 0 | 12.27K | 224.15K | 206.27K | 208.58K | 714.26K | 201.16K | 475.63M |
| Property, Plant & Equipment | 0 | 0 | 0 | 206.27K | 208.58K | 602.4K | 89.31K | 19.91M |
| Fixed Asset Turnover | - | - | - | - | - | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 12.27K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 224.15K | 0 | 0 | 111.86K | 111.86K | 455.95M |
| Total Assets | 214.65K▲ 0% | 216.74K▲ 1.0% | 1.06M▲ 386.9% | 22.94M▲ 2073.5% | 7.59M▼ 66.9% | 5.17M▼ 31.9% | 7.29M▲ 41.1% | 5.23B▲ 0% |
| Asset Turnover | - | - | - | - | - | - | - | 0.00x |
| Asset Growth % | - | 0.98% | 386.92% | 2073.5% | -66.92% | -31.87% | 41.1% | 132881.59% |
| Total Current Liabilities | 117.68K | 62.94K | 404.86K | 2.53M | 4.35M | 3.49M | 2.77M | 2.97B |
| Accounts Payable | 0 | 27.26K | 0 | 2.02M | 0 | 0 | 2.58M | 0 |
| Days Payables Outstanding | - | - | - | 17.33K | - | - | 1.76K | 8.37K |
| Short-Term Debt | 35.69K | 0 | 0 | 0 | 0 | 0 | 38.29K | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 30.53K | 0 | 27.06K | 0 | 0 |
| Other Current Liabilities | 0 | 35.69K | -1 | -2.02M | 0 | 0 | 26.11K | 2.97B |
| Current Ratio | 1.82x | 3.25x | 2.05x | 8.97x | 1.70x | 1.28x | 2.56x | 2.56x |
| Quick Ratio | 1.82x | 3.25x | 2.05x | 8.97x | 1.70x | 1.28x | 2.56x | 2.56x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 600.93K | 1.25M | 4.06M | 0 | 0 | 38.29K | 6.54M | 832.88M |
| Long-Term Debt | 436.21K | 927.81K | 2.09M | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 38.29K | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 164.72K | 323.5K | 1.97M | 0 | 0 | 0 | 6.54M | 840.36M |
| Total Liabilities | 718.61K | 1.31M | 4.46M | 2.53M | 4.35M | 3.53M | 9.31M | 3.8B |
| Total Debt | 471.9K | 927.81K | 2.09M | 0 | 0 | 450.57K | 38.29K | 0 |
| Net Debt | 258.92K | 723.34K | 1.26M | -20.83M | -4.97M | -2.32M | -5.77M | -2.84B |
| Debt / Equity | - | - | - | - | - | 0.27x | - | 0.00x |
| Debt / EBITDA | - | - | - | - | - | - | - | -0.00x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | 168.27x |
| Interest Coverage | - | -2.91x | -1.84x | -64.70x | -1.06x | -347.39x | -584.07x | -3431.07x |
| Total Equity | -503.97K▲ 0% | -1.1M▼ 117.8% | -3.41M▼ 210.5% | 20.4M▲ 698.7% | 3.24M▼ 84.1% | 1.64M▼ 49.4% | -2.02M▼ 223.0% | 1.43B▲ 0% |
| Equity Growth % | - | -117.77% | -210.54% | 698.68% | -84.12% | -49.37% | -223.03% | 86476.15% |
| Book Value per Share | -2621.96 | -171.30 | -427.15 | 1937.37 | 199.78 | 302.49 | -5.67 | 1710.46 |
| Total Shareholders' Equity | -503.97K | -1.1M | -3.41M | 20.4M | 3.24M | 1.64M | -2.02M | 1.43B |
| Common Stock | 764 | 764 | 464 | 1.29K | 2 | 63 | 103 | 84K |
| Retained Earnings | -510.78K | -1.12M | -3.46M | -10.31M | -27.87M | -46.42M | -63.2M | -84.42B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -11.8K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RNAZ Cash Flow Statement
TransCode Therapeutics, Inc. (RNAZ) cash flow — operating, investing & free cash flow history
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -299.57K | -508.51K | -492.97K | -5.27M | -15.76M | -18.07M | -13.34M | -13.34M |
| Operating CF Margin % | - | - | - | - | - | - | - | - |
| Operating CF Growth % | - | -69.74% | 3.06% | -968.4% | -199.28% | -14.67% | 26.22% | -17.84% |
| Net Income | -453.44K | -607.21K | -2.34M | -6.84M | -17.56M | -18.55M | -16.75M | -27.13M |
| Depreciation & Amortization | 0 | 0 | 0 | 42.47K | 98.61K | 516.75K | 534.86K | 192.25K |
| Stock-Based Compensation | 22.38K | 1.4K | 45.44K | 186K | 0 | 1.04M | 1.7M | 326.5K |
| Deferred Taxes | 0 | 0 | 0 | 876.19K | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 106.55K | 102.01K | 1.5M | 39.47K | 395.33K | 0 | 1.54M | 11.48M |
| Working Capital Changes | 24.94K | -4.7K | 309.76K | 432.39K | 1.31M | -1.08M | -351.48K | 617.46K |
| Change in Receivables | 0 | 0 | 0 | 0 | -360.23K | 360.23K | 0 | -185.91K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | -54.74K | 191.25K | 2.29M | 1.84M | 0 | 0 | 458.15K |
| Cash from Investing | 0 | 0 | 0 | -251.82K | -100.92K | -35.61K | -21.76K | -500 |
| Capital Expenditures | 0 | 0 | 0 | -254.82K | -100.92K | -35.61K | -21.76K | -500 |
| CapEx % of Revenue | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 3K | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 512.43K | 500K | 1.12M | 25.52M | 5.99K | 15.91M | 16.4M | 15.48M |
| Debt Issued (Net) | 550K | 500K | 1.19M | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 0 | 0 | 1000K | 5.99K | 1000K | 1000K | 2M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -37.57K | 0 | -73.48K | -818.55K | 0 | 0 | 0 | -455.73K |
| Net Change in Cash | 212.86K▲ 0% | -8.51K▼ 104.0% | 623.54K▲ 7428.9% | 20M▲ 3107.1% | -15.86M▼ 179.3% | -2.2M▲ 86.1% | 3.04M▲ 238.3% | 959.96K▲ 0% |
| Free Cash Flow | -299.57K▲ 0% | -508.51K▼ 69.7% | -492.97K▲ 3.1% | -5.52M▼ 1020.1% | -15.86M▼ 187.3% | -18.11M▼ 14.2% | -13.36M▲ 26.2% | -14.52M▲ 0% |
| FCF Margin % | - | - | - | - | - | - | - | - |
| FCF Growth % | - | -69.74% | 3.06% | -1020.09% | -187.29% | -14.16% | 26.24% | 8.52% |
| FCF per Share | -1558.57 | -79.37 | -61.78 | -524.28 | -977.96 | -3338.63 | -37.51 | -37.51 |
| FCF Conversion (FCF/Net Income) | 0.66x | 0.84x | 0.21x | 0.77x | 0.90x | 0.97x | 0.80x | 0.54x |
| Interest Paid | 0 | 0 | 0 | 17.87K | 0 | 32.86K | 16.63K | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RNAZ Key Ratios
TransCode Therapeutics, Inc. (RNAZ) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -80.53% | -148.57% | -759.85% | - | -1.9% |
| Return on Invested Capital (ROIC) | - | - | - | - | - | - | 3.6% |
| Debt / Equity | - | - | - | - | 0.27x | - | 0.00x |
| Interest Coverage | -2.91x | -1.84x | -64.70x | -1.06x | -347.39x | -584.07x | -3431.07x |
| FCF Conversion | 0.84x | 0.21x | 0.77x | 0.90x | 0.97x | 0.80x | 0.54x |
RNAZ SEC Filings & Documents
TransCode Therapeutics, Inc. (RNAZ) SEC filings — annual & quarterly reports (10-K, 10-Q)
RNAZ Frequently Asked Questions
TransCode Therapeutics, Inc. (RNAZ) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
TransCode Therapeutics, Inc. (RNAZ) grew revenue by 0.0% over the past year. Growth has been modest.
TransCode Therapeutics, Inc. (RNAZ) reported a net loss of $27.1M for fiscal year 2024.
Dividend & Returns
TransCode Therapeutics, Inc. (RNAZ) had negative free cash flow of $14.5M in fiscal year 2024, likely due to heavy capital investments.
Explore More RNAZ
TransCode Therapeutics, Inc. (RNAZ) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates